Is new-onset diabetes mellitus important? Yes, but...

High Blood Pressure and Cardiovascular Prevention

Volumn 15, Issue 1, 2008, Pages 5-8

  Alderman, Michael H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

blockers; ACE inhibitors; Angiotensin II receptor blockers; Antihypertensive drugs; Diuretics; Hypertension; New onset diabetes mellitus

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIURETIC AGENT; LISINOPRIL; PLACEBO; RAMIPRIL; ROSIGLITAZONE; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DISTRESS SYNDROME; DRUG EFFECT; DRUG INDICATION; DRUG USE; FOLLOW UP; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INCIDENCE; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE;

EID: 43049093731     PISSN: 11209879     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151642-200815010-00002     Document Type: Note

References (20)

1. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin dependent diabetes. In: Diabetes in America. 2nd ed. Bethesda (MD): National Institutes of Health, 1995
2. Fang J, Alderman MH. Impact of increasing burden of diabetes on acute myocardi-al infarction in New York City 1990-2000. Diabetes 2006; 55: 768-73
3. Centers for Disease Control and Prevention. Prevalence of self-reported cardio-vascular disease among persons aged ≥35 years with diabetes - United States 1977-2005. MMWR Morb Mortal Wkly Rep 2007; 56 (43): 1129-324.
4. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97
6. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-62
7. Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28: 2261-6
8. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130-4
9. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-9
10. Eberly LE, Cohen JD, Prineas R, et al. Intervention Trial Research group. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care 2003; 26: 848-54
11. Almgren T, Wilhelmsen L, Samuelsson O, et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007; 25: 1311-7
12. Aksnes TA, Kjeldsen SE, Rostrup M, et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial population. Hypertension 2007; 50: 467-73
13. Alderman MH, Lamport B. Labelling of hypertensives: a review of the data. J Clin Epidemiol 1990; 43 (2): 195-200
14. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-35
15. Rowe JW, Tobin JD, Rosa RM, et al. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 1980; 29: 498-502
16. Barzilay JI, Cutler JA, Davis BR. Antihypertensive medications and risk of diabetes melelitus. Curr Opin Nephrol Hypertens 2007; 16: 256-60
17. Kostis JB, Wilson AC, Freudenberger RS, et al. SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29-35
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
19. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22